Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
81.20
-4.40 (-5.14%)
At close: Mar 27, 2026
Market Cap126.10B -11.9%
Revenue (ttm)38.04M -14.4%
Net Income-351.92M
EPS-0.23
Shares Out1.55B
PE Ration/a
Forward PE34.41
Dividendn/a
Ex-Dividend Daten/a
Volume15,721,190
Average Volume9,749,493
Open85.00
Previous Close85.60
Day's Range79.70 - 85.30
52-Week Range54.10 - 277.00
Beta0.46
RSI17.18
Earnings DateMay 5, 2026

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6919
Full Company Profile

Financial Performance

In 2025, TPE:6919's revenue was 38.04 million, a decrease of -14.40% compared to the previous year's 44.43 million. Losses were -351.92 million, -40.23% less than in 2024.

Financial Statements